surmount-1 tirzepatide non-diabetic obesity weight loss For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The SURMOUNT-5: Tirzepatide Bests Semaglutide in

Severe Gastrointestinal Adverse Reactions Use of OZEMPIC has been associated with gastrointestinal adverse reactions, sometimes severe [see ADVERSE REACTIONS ]

Severe Allergic Reactions Though rare, allergic reactions can occur

Colpitts et al., 2017)

It may sound unreal, but many of your favorite products are currently available at lower prices

Both forms deliver identical active compounds from licensed 503A compounding pharmacies, ensuring pharmaceutical quality regardless of delivery route

Insomnia is not listed among common adverse reactions in FDA prescribing information, and clinical trials did not identify it as a statistically significant side effect